氟尿嘧啶为主方案持续和间断输注治疗晚期结直肠癌  被引量:1

Continuous vs intermittent infusion of fluorouracil in advanced colorectal cancer

在线阅读下载全文

作  者:朱玉芬[1] 张瑞芳[1] 邹海萍[1] 宋淼皓[1] 王德兴[1] 杨晓燕[1] 

机构地区:[1]上海市徐汇区中心医院肿瘤科,上海200031

出  处:《中国癌症杂志》2002年第5期416-418,共3页China Oncology

基  金:上海市徐汇区卫生局专项科研基金资助(No:C98-8)

摘  要:目的:比较氟尿嘧啶(5-FU)持续静脉输注120小时和每天静脉输注2小时,连续5天的两种给药方法治疗晚期结直肠癌的近期疗效和不良反应。方法:17例晚期结直肠癌患者接受5-FU 2.5g+5%葡萄糖注射液100 m1置入Baxter公司生产的049002便携式泵持续输注120小时(A组);16例晚期结直肠癌患者接受5-FU500mg+5%葡萄糖注射液500 ml每天输注2小时,连续5天(B组)。33例均联合亚叶酸钙(CF)200 mg+5%葡萄糖注射液100 ml输注1小时,连续5天;羟基喜树碱(HCPT)10 mg+5%葡萄糖注射液250ml输注2小时,连续6天。每3~4周为1疗程,连续2疗程后进行疗效评价。结果:A组17例中CR 1例,PR 8例,RR 52.94%,B组16例中CR 0例,PR 3例,RR 18.75%。两组疗效x^2检验有差异(P<0.05)。不良反应主要有白细胞下降、口腔溃疡、呕吐和腹泻,经Wiloxon秩和检验,两组结果差异无显著性(P值>0.05)。结论:5-FU持续静脉输注120小时方法治疗晚期结直肠癌的近期疗效优于间断静脉输注方法,而且毒性可以耐受,尤其适宜老年患者。Purpose:To compare the therapeutic and adverse effects between continuous and intermittent infusion of fluorouracil(5-FU) in advanced colorectal cancer.Methods:17 patients of advanced colorectal cancer were treated with continuous intravenous infusion of 5-FU 2.5g in 100 ml of 5% glucose in a continuous infusions pump,for 120 h (Group A).16 patients of similar severity were treated with 5-FU 500 mg in 500 ml of 5% glucose 2 h iv daily for 5 d (Group B). Total of 33 patients were treated with calcium folinate (CF) 200 mg in 100 ml of 5% glucose 1 h iv daily for 5 d and HCPT 10 mg in 250 ml of 5% glucose 2 h iv daily for 6d.The therapeutic and adverse effects were evaluated according to the cri- teria recommended by WHO.Results:Effectiveness was noted in 9 patients in Group A and 3 patients in group B.(x^2 test P<0.05).Adverse effects were similar between the 2 groups (Wilcoxon test).Conclusions:Continuous intravenous in- fusion of 5-FU is better than intermittent drug administration schedule.

关 键 词:治疗 晚期 结直肠肿瘤 亚叶酸钙 氟尿嘧啶 羟基喜树碱 持续静脉输注 

分 类 号:R735.35[医药卫生—肿瘤] R735.37[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象